Population PK/PD of Off Label Drugs in Premature Neonates

Overview

This study will provide information on the pharmacokinetics, safety and effectiveness of off--label drugs used in critically ill premature infants: doxapram, fentanyl, midazolam, paracetamol, phenobarbital, sildenafil, levetiracetam, ibuprofen and fluconazole. PK/PD analysis with NONMEM (non-linear mixed effects modelling) will result in (adapted) dosage guidelines, thus contributing towards an improvement in the quality of care and cost efficiency. Furthermore the development of Dried Blood Spot (DBS) analysis is investigated for these drugs as a minimally invasive method for conventional patient care and to perform pharmacological studies in children. The adapted dosage guidelines will be implemented directly into clinical practice in collaboration with the NKFK. Therefore the study is designed as an observational multicenter study to be able to collect sufficient data for the drugs of interest.

BACKGROUND Approximately 60% of drugs are used off--label in critically ill neonates in the Neonatal Intensive Care Units (NICU). This is even more true for pre--term born neonates in whom pharmacokinetics of these agents may be different due to immature elimination pathways. The lack of sufficient data about efficacy and safety of many of these drugs makes it difficult to have evidence based dosing guidelines for these agents. Therefore the urge for drug research in this population is of great importance. The pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of drugs in premature infants are different from the characteristics found in term neonates, older children and adults. These differences are caused among others by a different body composition, by immaturity of the renal excretion systems, the metabolic pathways in the liver and other organ functions as well as immature drug receptors and transporters. After birth, there is a rapid development of many of these functions, necessitating frequent adaptation of dosage guidelines in the first few weeks of life. Besides age and size, co--morbidity, co--administration of drugs and genetic heterogeneity may further contribute to this extensive inter--individual variability in pharmacokinetics and pharmacodynamics of premature infants. There is a critical lack of evidence--based data of drug dosing in (extremely) preterm neonates. OBJECTIVE Recently, population PK/PD modeling and simulation studies have enabled the development of evidence--based individualized dosing schemes for children with a limited number of subjects, thus improving drug safety and efficacy. The application of PK/PD modeling in the most critically ill population of premature infants, with the highest variability in the pharmacokinetics of drugs, and the greatest lack of adequate data underscoring optimal dosage, can contribute to the development of rational, individualized and safe dosing regimens. This study will provide information on the pharmacokinetics, safety and effectiveness of off--label drugs used in critically ill premature infants: doxapram, fentanyl, midazolam, paracetamol, phenobarbital, sildenafil, levetiracetam, ibuprofen and fluconazole (only studied for the PK). PK/PD analysis will result in (adapted) dosage guidelines, thus contributing towards an improvement in the quality of care and cost efficiency. Furthermore the development of Dried Blood Spot (DBS) analysis is investigated for these drugs as a minimally invasive method for conventional patient care and to perform pharmacological studies in children. The adapted dosage guidelines will be implemented directly into clinical practice in collaboration with the NKFK. Therefore the study is designed as an observational multicenter study to be able to collect sufficient data for the drugs of interest. DESIGN This is a prospective observational multicenter study on the pharmacokinetics and pharmacodynamics of paracetamol, fentanyl, midazolam, phenobarbital, doxapram, levetiracetam, sildenafil, ibuprofen and fluconazole routinely administered to preterm infants according to standard protocols. The treatment regimen is left to the discretion of the treating physician in accordance with current guidelines. During this study a limited number of additional blood samples will be drawn from the participants for pharmacokinetic analysis, never exceeding 3% of the total blood volume during any four--week period or 1% at any single time. It is standard care in the Netherlands for all premature born infants under 32 weeks to get seen by the paediatrician at the age of two years for a check on growth and development. The visit to the day care clinic of the hospital of their admission on birth, enables us to collect qualitative data on growth and physiological development as well as from psychological and neurodevelopmental standardised tests.The collected data enables us to gain a better description of the subjects in our study and to further determine safety of the studied drugs. POPULATION All preterm infants born with gestational age \< 32 weeks who are admitted to one of the participating NICUs are eligible for inclusion. The participating departments are all level III Neonatal Intensive Care Units. Three are situated in an academic hospital (Rotterdam, Nijmegen and Maastricht) and one in a non--academic hospital (Veldhoven). Patients admitted to the 4 NICUs consist of both inborn and outborn neonates with different gestational ages (24--42 weeks). All admitted patients need intensive or high care treatment. Most patients will be admitted on the first postnatal day, but sometimes are referred at older post natal ages (\<14 days) to the NICU. OUTCOME Primary study parameters/outcome of the study: 1\) Pharmacokinetic endpoints for all 9 drugs are clearance en volume of distribution. Secondary study parameters/outcome of the study (if applicable): Pharmacodynamics of paracetamol, fentanyl, midazolam, phenobarbital, doxapram, levetiracetam and sildenafil will be explored in all included preterm neonates. Fluconazole will only be studied for the pharmacokinetics. Drug specific effects of drugs (e.g. pain scores for morphine, blood pressure for dopamine) as well as side effects and short term effects on morbidity and outcome will be analyzed. Additional pharmacodynamic endpoints for the 7 PK/PD study drugs is the drug target concentration for each drug that is related to the desired effect. The parameters to measure the effect of the drugs: 1. Fentanyl and paracetamol, used as analgetics; clinical endpoint is pain relief, as routinely measured by the validated COMFORTneo scale and the NRS (numeric rating scale) scale. 2. Midazolam, phenobarbital and levetiracetam, used as anticonvulsive drugs; clinical endpoint is control of convulsions, measured by Cerebral Function Monitoring using amplitude--integrated EEG (aEEG). 3. Midazolam and fentanyl, used as a sedative drug during endotracheal intubation; clinical endpoint is the intubation readiness score (IRS) and a qualitative intubation score and sedation score. 4. Midazolam and fentanyl, used as a sedative drug during nursing care is measured by the COMFORTneo scale. 5. Doxapram, used as treatment for neonatal apnea; clinical endpoint is control of neonatal apnea and endotracheal intubation in case of failure. The first endpoint can be measured by modern monitoring technology, in which central post--monitoring data stored after initiation of treatment will reveal the effect of doxapram on the reduction or elimination of apneas. 6. Sildenafil, a treatment for PH (pulmonary hypertension); clinical endpoints are level of ventilatory support, oxygen need (repetitive oxygenation index analyses) and BPD (broncho pulmonary dysplasia) development. 7. Ibuprofen is used to close patent ductus arteriosus (PDA) in different dosages, orally and intravenously in the recruiting sites. Endpoints are measured by cardiac ultrasound: ductus closure (yes/no), ductal diameter and LA/AO ratio Inter-- and intra--patient variability of the PD and PK parameters of the drugs to be investigated. Parameters with effect on this variability will be identified. Tertiary outcome: 1. Development of a minimally invasive Dried Blood Spot analysis method to perform future pharmacokinetic studies in neonates. The measured concentration of the drugs in the dried blood spot samples will be compared with the concentration of the blood samples in the vial, which is the current validated standard method. The validity of the DBS method will be the endpoint. 2. Influence of specific polymorphisms involved in the metabolism of the investigated drugs.